Your session is about to expire
← Back to Search
89Zr-DFO-REGN3767 PET Scan for Non-Hodgkin's Lymphoma
Phase < 1
Waitlist Available
Led By Neeta Pandi-Taskar, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients must have eGFR >50 mL/min/1.73m2.
Measurable disease by Lugano criteria, with at least one lesion outside of the liver
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
This trialwill study the safety and effectiveness of a new drug to understand how it moves through the body.
Who is the study for?
This trial is for people with a type of cancer called Diffuse Large B Cell Lymphoma. They must have measurable disease, at least one lesion outside the liver, and good kidney function (eGFR >50 mL/min/1.73m2). It's not for those who've had severe side effects from immune therapies or haven't recovered from recent cancer treatments.Check my eligibility
What is being tested?
Researchers are testing a substance called 89Zr-DFO-REGN3767 in PET scans to see how it's processed by the body, determine the best dose, and find out when is the optimal time to perform PET scanning after its injection.See study design
What are the potential side effects?
Potential side effects may include reactions related to injection such as pain or discomfort at the site of injection, allergic reactions to components of 89Zr-DFO-REGN3767, and any typical risks associated with undergoing PET/CT scans.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My kidney function is good.
Select...
I have a cancerous lesion outside my liver that can be measured.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Biodistribution of 89Zr-DFO-REGN3767
Optimal 89Zr-DFO-REGN3767 mass dose for tumor targeting
Optimal time for imaging and tumor uptake post 89Zr-DFO-REGN3767 administration
+1 moreTrial Design
4Treatment groups
Experimental Treatment
Group I: Cohort 4Experimental Treatment2 Interventions
Up to 3 participants will be enrolled to receive a total 20mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
Group II: Cohort 3Experimental Treatment2 Interventions
Up to 3 participants will be enrolled to receive a total 10mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
Group III: Cohort 2Experimental Treatment2 Interventions
Up to 3 participants will be enrolled to receive a total 5mg of 89Zr-DFO-REGN3767 (+REGN3767) total antibody mass for PK and serial imaging with 3 PET/CT scans
Group IV: Cohort 1Experimental Treatment2 Interventions
Up to 3 participants will be enrolled to receive a single dose of 89Zr-DFO-REGN3767 (total 2mg antibody mass). Participant to undergo 3 PET/CT scans and concurrent blood draws for PK
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET/CT
2022
Completed Phase 3
~1240
Find a Location
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,936 Previous Clinical Trials
588,919 Total Patients Enrolled
Neeta Pandi-Taskar, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My kidney function is good.I haven't had radiation in the last 2 weeks or have recovered from its side effects.I am not pregnant, breastfeeding, and if applicable, have been postmenopausal for at least 12 months.I have mostly recovered from side effects of previous cancer treatments, except for mild, stable conditions.I stopped taking cancer immune therapy because of its side effects.I have a cancerous lesion outside my liver that can be measured.
Research Study Groups:
This trial has the following groups:- Group 1: Cohort 3
- Group 2: Cohort 2
- Group 3: Cohort 1
- Group 4: Cohort 4
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there opportunities for recruitment in this trial?
"Per the clinicaltrials.gov website, this research project is still recruiting participants. It was initially posted on September 11th 2020 and most recently revised on October 3rd 2022."
Answered by AI
What is the current enrollment quota for this research endeavor?
"Affirmative. Clinicaltrials.gov data indicate that this study, which was first published on September 11th 2020, is actively enrolling participants. In total, 20 patients must be recruited from one medical site to complete the trial."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger